Trial Profile
An open label, multicentre, phase I/II dose escalation trial of carfilzomib in combination with doxorubicin and dexamethasone (CAD) therapy in transplant eligible relapsed myeloma patients
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 03 Dec 2012
Price :
$35
*
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Doxorubicin
- Indications Multiple myeloma
- Focus Adverse reactions; Therapeutic Use
- Acronyms MUK-02
- 26 Nov 2012 Status changed from unconfirmed to discontinued as reported by ISRCTN: Current Controlled Trials.
- 16 May 2011 New trial record